Deutetrabenazine
CAS No : 1392826-25-3
General description:
Deutetrabenazine is an active pharmaceutical ingredient (API) used for the treatment of movement disorders such as chorea associated with Huntington’s disease and tardive dyskinesia. It is a deuterated form of tetrabenazine and functions as a reversible inhibitor of vesicular monoamine transporter 2 (VMAT2), helping to regulate the release of neurotransmitters in the central nervous system.
The incorporation of deuterium atoms improves the metabolic stability of the molecule, resulting in a more favorable pharmacokinetic profile. Deutetrabenazine is manufactured under stringent quality and regulatory standards to ensure high purity, consistent potency, and reliable performance. It is suitable for formulation development, clinical research, and commercial pharmaceutical manufacturing.
The incorporation of deuterium atoms improves the metabolic stability of the molecule, resulting in a more favorable pharmacokinetic profile. Deutetrabenazine is manufactured under stringent quality and regulatory standards to ensure high purity, consistent potency, and reliable performance. It is suitable for formulation development, clinical research, and commercial pharmaceutical manufacturing.
Chemical Structure:
